LOGIN
ID
PW
MemberShip
2025-07-21 04:17
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Opinion
[Reporter's View] Divisional restructuring needed
by
Lee, Hye-Kyung
Jun 30, 2025 06:06am
During his candidacy, President Lee Jae-myung pledged to designate the biotech industry as a cutting-edge sector and build it as the future growth engine, aiming to position South Korea as one of the world's five strongest biotech countries. Based on an analysis that the previous government was short on investment in the pharmaceutical and bi
Policy
More generic 'Vimovo' drugs with naproxen+PPI enters the mkt
by
Lee, Tak-Sun
Jun 30, 2025 06:05am
Generic drugs containing the same active ingredients as the 'Vimovo' (naproxen+esomeprazole magnesium trihydrate), a combination of an anti-inflammatory drug and an anti-ulcer agent, are set to be released. A generic has not been approved since Chong Kun Dang's 'Naxen S Tab' was approved in 2024. Considering the characteristics of a generi
Policy
Polivy granted partial reimbursement after 5 years
by
Lee, Tak-Sun
Jun 30, 2025 06:05am
Roche¡¯s Polivy (polatuzumab vedotin), a treatment for diffuse large B-cell lymphoma (DLBCL) that is currently non-reimbursed in Korea, has been added to the reimbursement list as a part of combination therapy. With the listing, the other drugs used in the combination, excluding Polivy, will be reimbursed. This measure is in accordance wi
Opinion
[Reporter's View] For local gov't seeking biotech diplomacy
by
Whang, byung-woo
Jun 30, 2025 06:05am
'BIO USA,' held in Boston, U.S., is the world's largest biotech industry conference. Notably, this year's conference was attended by officials from Korea's local government. The attending officials aimed to promote local biotech clusters and seek potential investment partners. Through this event, they intended to establish a gamer-changer
Company
88% registered APIs imported from China or India
by
Kim, Jin-Gu
Jun 27, 2025 06:04am
Amid a surge in the number of drug master file registrations in the first half of this year, the share of raw materials from China and India rose to 88.2%. This is a sharp increase compared to the average of 62.1% share the two countries had during the past 5 years. This is attributed to the large number of previously delayed raw material dru
Policy
Ensuring stable supply of drugs in short supply
by
Lee, Jeong-Hwan
Jun 27, 2025 06:03am
Following President Lee Jae-myung's pledge to establish a stable supply system for drugs with supply shortages, attention is drawn to the Ministry of Health and Welfare's (MOHW) opinion that a social consensus on the criteria and scope of 'supply shortage' is first needed. It is anticipated that legislative review in the National Assembly
Company
Tevimbra adds esophageal, gastric, lung cancer indications
by
Whang, byung-woo
Jun 27, 2025 06:02am
BeiGene Korea (Name to be changed to BeOne Medicine Korea) announced that its immuno-oncology drug Tevimbra (tislelizumab) has been approved by the Ministry of Food and Drug Safety for additional indications for esophageal cancer, gastric cancer, and non-small cell lung cancer. With the additional approval, Tembriva can now be used as a fi
Company
KPTA ¡®KOR-CHN-JPN supply cooperation to bring $12B effect'
by
Kim, Jin-Gu
Jun 27, 2025 06:02am
The Korea Pharmaceutical Traders Association (KPTA), China Chamber of Commerce for Import & Export of Medicines & Health Products (CCMPHIE), and Japan Pharmaceutical Traders Association (JPTA) announced on June 25 that they signed a memorandum of understanding (MOU) for the stabilization of the pharmaceutical supply chain at the Korea Pavi
Company
¡®Wegovy, a game-changer for high-risk obesity patients¡¯
by
Whang, byung-woo
Jun 26, 2025 06:08am
Obesity is a cause of various metabolic syndromes and a major risk factor for cardiovascular disease. In fact, approximately 80% of patients hospitalized for cardiovascular disease are obese, and studies have shown that the risk of cardiovascular events in obese patients is up to twice as high as in those of normal weight. Over the past 20 ye
Company
The 2nd KRAS-targeted cancer drug 'Krazati' expected
by
Eo, Yun-Ho
Jun 26, 2025 06:08am
The second KRAS inhibitor is expected to be commercialized in South Korea. Bristol Myers Squibb (BMS) Korea recently submitted a marketing authorization application to the Ministry of Food and Drug Safety (MFDS) for its anti-cancer drug, Krazati (adagrasib). Krazati was also designated as an orphan drug in January. It is indicated for
1
2
3
4
5
6
7
8
9
10
>